Clinical Outcomes of Patients with AmpC-Beta-Lactamase-Producing Enterobacterales Bacteremia Treated with Carbapenems versus Non-Carbapenem Regimens: A Single-Center Study.
Orjowan ShalabiLivnat KashatOmer MurikShoshana ZevinMarc V AssousEli Ben-ChetritPublished in: Antibiotics (Basel, Switzerland) (2024)
Empiric and definitive non-carbapenem regimens for bacteremia with AmpC-producing organisms were not associated with treatment failure or increased 30-day mortality. Ciprofloxacin appears promising for selected, stable patients, potentially enabling early discharge.
Keyphrases
- gram negative
- multidrug resistant
- acinetobacter baumannii
- newly diagnosed
- end stage renal disease
- klebsiella pneumoniae
- ejection fraction
- pseudomonas aeruginosa
- peritoneal dialysis
- prognostic factors
- drug resistant
- squamous cell carcinoma
- coronary artery disease
- risk factors
- cardiovascular disease
- escherichia coli
- locally advanced
- urinary tract infection